The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The study evaluates elecoglipron and shows improvements in glycemic control and body weight compared with placebo.

The award recognizes his scientific career and his contribution to research and clinical care in multiple sclerosis.

The grants support projects led by Drs. María José Buzón, María Buti, Elena Élez, and Maria Vieito.

The study is expected to contribute to the identification of new therapeutic targets and the development of nutritional strategies to improve health.

The funds have supported projects at the Vall d’Hebron Research Institute (VHIR) and the Vall d’Hebron Institute of Oncology (VHIO) focused on pancreatic cancer.

The event brought together experts from the Vall d’Hebron Institute of Research (VHIR) and the Institute of Geosciences of Barcelona to analyze how environmental factors and the climate crisis impact population health.

The event, held at VHIR, has presented applied experiences and discussion forums with experts in the field to promote more inclusive research.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

AIDAY 2026 showcased the artificial intelligence initiatives, infrastructures and projects already being developed across the Campus.

All patients showed a favorable clinical course and responded well to antibiotic treatment, without complications.

The donation will support the continued development of a gene therapy strategy based on silencing the altered gene and restoring GNB1 protein function for the treatment of this ultra-rare encephalopathy.

In 2025, the institute had 688 active trials, with a special focus on rare diseases and pediatrics.

Researchers from the Vall d’Hebron Research Institute (VHIR) have participated in a study showing that, after just a few seconds of illumination, the activated molecule prevents the formation of tumor spheres.

The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.

A project led by the Vall d’Hebron Research Institute (VHIR) in collaboration with FIDMAG Germanes Hospitalàries Research Foundation describes structural and functional brain changes in adolescents with borderline personality disorder (BPD).

The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.

As part of Europe Day, the second official presentation of the VHIR Central Building was held, with patient associations taking a leading role.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

Science and creativity come together in the first Catalan literary competition at VHIR.

This weekend, the Vall d’Hebron Research Institute (VHIR) has once again taken part in the Science Festival 2026 with a diverse and participatory program that has focused on health, innovation, and citizen engagement in research.

This consists of three hands-on training workshops in which predoctoral researchers have developed new outreach proposals based on their research, with professional guidance and support.

The accumulation of metabolic products within cardiac cells alters their function and accelerates the deterioration of heart tissue with age.

The proposal focuses on automatic speech analysis as a digital biomarker for the early detection and monitoring of depression.